Where Can You Report Your Adverse Drug Reactions Or Adverse Events Following Immunization

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.

How to report

You can send the case reports using the following tools:

For Healthcare Professionals and the Public

The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.

The VigiMobile e-Form and e-Reporting e-Form:

The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones

Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Apple IOS Phones

Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows

Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed

Scan QR Codes to Report:

ADRs Following Medication Use	AEFIs Following Vaccine Use

Or use the following link: LNPVP: e-Reporting eForm	Or use the following link: LNPVP: VigiMobile eForm

Direct Contact with the Lebanese National Pharmacovigilance Program:

You may contact the Lebanese National Pharmacovigilance Program through:

Email Address:

pv@moph.gov.lb, pv.moph@gmail.com

Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254

For Market Authorization Holders:

Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.

As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
G04BE03	SILDENAFIL ARROW LAB	G	Sildenafil - 100mg	100mg	Tablet, film coated	3,192,970 L.L
A07EC02	SALCROZINE	G	Mesalazine - 500mg	500mg	Tablet, gastroresistant	2,013,076 L.L
G04BE03	SILDENAFIL STRAGEN	G	Sildenafil - 20mg	20mg	Tablet, coated	38,048,630 L.L
A07EC02	SALCROZINE	G	Mesalazine - 1g	1g	Tablet, gastroresistant	4,073,187 L.L
S03AA30	SULFACHLOR	G	Sulfacetamide sodium - 110mg/ml, Chloramphenicol - 5mg/ml		Drops solution	202,216 L.L
A07EC02	SALCROZINE	G	Mesalazine - 500mg	500mg	Suppository	576,508 L.L
A07EC02	SALCROZINE	G	Mesalazine - 1000mg	1000mg	Suppository	2,306,034 L.L
N01AH03	SUFENTANIL RENAUDIN	G	Sufentanil (citrate) - 250mcg/5ml	250mcg/5ml	Injectable solution	3,524,899 L.L
N01AH03	SUFENTANIL RENAUDIN	G	Sufentanil (citrate) - 5mcg/ml	10mcg/2ml	Injectable solution	755,239 L.L
P01AB01	SOLUFLEX METRONIDAZOLE	G	Metronidazole - 500mg/100ml	500mg/100ml	Injectable solution	162,541 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
P01AB07	SNAD	G	Secnidazole - 500mg	500mg	Tablet	774,053 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
J01MA02	SUPERFLOX	G	Ciprofloxacine (HCl) - 500mg	500mg	Tablet, film-scored	458,250 L.L
N03AX09	SEIZET 25	G	Lamotrigine - 25mg	25mg	Tablet, dispersible/ chewable	573,821 L.L
P01AB07	SECNOL	G	Secnidazole anhydre - 2g	2g	Granules	842,589 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
P01AB07	SECNOL	G	Secnidazole - 2g	2g	Granules	842,589 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	205,703 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	221,792 L.L
C05AA01	SEDIPROCT	G	Hydrocortisone - 500mg, Cinchocaine HCl - 500mg		Cream	290,270 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	185,018 L.L
C05AA01	SEDIPROCT	G	Hydrocortisone - 5mg, Cinchocaine HCl - 5mg, Framycetin sulfate - 10mg, Esculoside - 10mg		Suppository	237,860 L.L
C05AA01	SINAHEAL-H	G	Hydrocortisone acetate - 5mg, Lidocaine - 60mg, Zinc oxide - 400mg, Aluminium Subacetate - 50mg		Suppository	501,253 L.L
C05AA01	SINAHEAL-H	G	Hydrocortisone acetate - 0.275g/100g, Lidocaine - 5g/100g, Zinc oxide - 18g/100g, Aluminium Subacetate - 3.5g/100g		Ointment	330,585 L.L
C10AA07	SINLIP	G	Rosuvastatin (calcium) - 10mg	10mg	Tablet, film coated	563,070 L.L
N05BA25	SEDOXIL	G	Mexazolam - 1mg	1mg	Tablet	1,705,336 L.L

...